These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26987523)

  • 1. Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis.
    Hutchinson LG; Gaffney EA; Maini PK; Wagg J; Phipps A; Byrne HM
    J Theor Biol; 2016 Jun; 398():162-80. PubMed ID: 26987523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
    Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth.
    Arakelyan L; Vainstein V; Agur Z
    Angiogenesis; 2002; 5(3):203-14. PubMed ID: 12831061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?
    Helfrich I; Schadendorf D
    Mol Oncol; 2011 Apr; 5(2):137-49. PubMed ID: 21345752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak.
    Gallagher DC; Bhatt RS; Parikh SM; Patel P; Seery V; McDermott DF; Atkins MB; Sukhatme VP
    Clin Cancer Res; 2007 Apr; 13(7):2115-20. PubMed ID: 17404094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo.
    Suzuki R; Yamamoto H; Ngan CY; Ohtsuka M; Kitani K; Uemura M; Nishimura J; Takemasa I; Mizushima T; Sekimoto M; Minamoto T; Doki Y; Mori M
    Int J Oncol; 2013 Nov; 43(5):1447-55. PubMed ID: 23982687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis.
    Deng X; Szabo S; Khomenko T; Tolstanova G; Paunovic B; French SW; Sandor Z
    Curr Pharm Des; 2013; 19(1):17-28. PubMed ID: 22950505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
    Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
    Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours.
    Coutelle O; Schiffmann LM; Liwschitz M; Brunold M; Goede V; Hallek M; Kashkar H; Hacker UT
    Br J Cancer; 2015 Feb; 112(3):495-503. PubMed ID: 25562438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization of the vasculature for treatment of cancer and other diseases.
    Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
    Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?
    Moon WS; Rhyu KH; Kang MJ; Lee DG; Yu HC; Yeum JH; Koh GY; Tarnawski AS
    Mod Pathol; 2003 Jun; 16(6):552-7. PubMed ID: 12808060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiopoietin-1, but not platelet-derived growth factor-AB, is a cooperative stimulator of vascular endothelial growth factor A-accelerated endothelial cell scratch closure.
    Alter A; Schmiedeck D; Fussnegger MR; Pries AR; Freesmeyer WB; Zakrzewicz A
    Ann Vasc Surg; 2009 Mar; 23(2):239-45. PubMed ID: 18973985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy.
    Elebiyo TC; Rotimi D; Evbuomwan IO; Maimako RF; Iyobhebhe M; Ojo OA; Oluba OM; Adeyemi OS
    Cancer Treat Res Commun; 2022; 32():100620. PubMed ID: 35964475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy.
    Gee MS; Procopio WN; Makonnen S; Feldman MD; Yeilding NM; Lee WM
    Am J Pathol; 2003 Jan; 162(1):183-93. PubMed ID: 12507901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.